Abstract
Plant-based expression technologies for recombinant proteins have begun to receive acceptance for pharmaceuticals and other commercial markets. Protein products derived from plants offer safer, more cost-effective, and less capital-intensive alternatives to traditional manufacturing systems using microbial fermentation or animal cell culture bioreactors. Moreover, plants are now known to be capable of expressing bioactive proteins from a diverse array of species including animals and humans. Methods development to assess the quality and performance of proteins manufactured in plants are essential to support the QA/QC demands as plant-produced protein products transition to the commercial marketplace. Within the pharmaceutical arena, process validation and acceptance criteria for biological products must comply with the Food and Drug Administration (FDA) and ICH Q6B guidelines in order to initiate the regulatory approval process. Detailed product specifications will also need to be developed and validated for plant-made proteins for the bioenergy, food, chemical synthesis, or research reagent markets.
We have, therefore, developed assessment methods for important qualitative and quantitative parameters of the products and the manufacturing methods utilized in plant-based production systems. In this chapter, we describe a number of procedures to validate product identity and characteristics including mass analyses, antibody cross-reactivity, N-terminal sequencing, and bioactivity. We also address methods for routine assessment of yield, recovery, and purity. The methods presented are those developed for the synthesis and recovery of the avian cytokine, chicken interleukin-12 (ChIL-12), produced in the leaves of Nicotiana benthamiana. The ChIL-12 protein used as a model for this chapter includes a C-terminal histidine epitope (HIS-tag) and, thus, these methods may be directly applicable to other HIS-tagged proteins produced in plants. However, the overall strategy presented using the ChIL-12HIS example should provide the basis of standard procedures for assessing the quality of other plant-based protein products and manufacturing systems.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Liu C, Towler M, Medrano G, et al (2009) Production of mouse interleukin-12 is greater in tobacco hairy roots grown in a mist reactor than in an airlift reactor. Biotechnol. Bioeng. 102, 1074–1086.
Medrano G, Reidy M, Liu J, et al (2009) Rapid system for evaluating bioproduction capacity of complex pharmaceutical proteins in plants. In: Faye L, and Gomord V (eds). Methods Mol Biol Humana Press, Totowa, NJ 483, 51–67.
Medrano G, Dolan MC, Stephens NT, et al (2010) Efficient plant-based production of chicken interleukin-12 yields a strong immunostimulatory cytokine. J. Interferon Cytokine Res. 30, 143–154.
Condori J, Medrano G, Sivakumar G, et al (2009) Functional characterization of a stilbene synthase gene using a transient expression system in planta. Plant Cell Rep. 28, 589–599.
Cramer CL, Boothe JG, Oishi KK (1999) Transgenic plants for therapeutic proteins: linking upstream and downstream strategies. Curr. Top. Microbiol. Immunol. 240, 95–118.
Cramer CL, Weissenborn DL, Oishi KK, et al (1996) Bioproduction of human enzymes in transgenic tobacco. Ann. N.Y. Acad. Sci. 792, 62–71.
Liu J, Dolan MC, Reidy M, et al (2008) Expression of bioactive single-chain murine IL-12 in transgenic plants. J. Interferon Cytokine Res. 28, 381–392.
Daniell H, Singh ND, Mason H, et al (2009) Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci. 14, 669–679.
Tremblay R, Wang D, Jevnikar AM, et al (2010) Tobacco, a highly efficient green bioreactor for production of therapeutic proteins. Biotechnol. Adv. 28, 214–221.
Wang DJ, Brandsma M, Yin Z, et al (2008) A novel platform for biologically active recombinant human interleukin-13 production. Plant Biotechnol. J. 6, 504–515.
Matoba N, Kajiura H, Cherni I, et al (2009) Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Plant Biotechnol. J. 7, 129–145.
Conley AJ, Joensuu JJ, Menassa R, et al (2009) Induction of protein body formation in plant leaves by elastin-like polypeptide fusions. BMC Biol. 7, 48.
Alvarez ML, Topal E, Martin F, et al (2010) Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation. Plant Mol. Biol. 72, 75–89.
Hood EE, Bailey MR, Beifuss K, et al (2003) Criteria for high-level expression of a fungal laccase gene in transgenic maize. Plant Biotechnol. J. 1, 129–140.
Torrent M, Llompart B, Lasserre-Ramassamy S, et al (2009) Eukaryotic protein production in designed storage organelles. BMC Biol. 7, 5.
Schillberg S, Twyman RM, Fischer R (2005) Opportunities for recombinant antigen and antibody expression in transgenic plants – technology assessment. Vaccine 23, 1764–1769.
Reed DG, Nopo-Olazabal LH, Funk V, et al (2005) Expression of functional hexahistidine-tagged ricin B in tobacco. Plant Cell Rep. 24, 15–24.
Hood E, Cramer CL, Medrano G, et al (2012) Protein targeting: strategic planning for optimizing protein products through plant biotechnology. In: Altman A, Hasegawa PM (eds). Plant Biotechnology and Agriculture: Prospects for the 21st Century. San Diego, CA: Elsevier Inc. doi:10.1016/B978-0-12-381466-1.00003-1.
Lambrecht B, Gonze M, Meulemans G, et al (2000) Production of antibodies against chicken interferon-gamma: demonstration of neutralizing activity and development of a quantitative ELISA. Vet. Immunol. Immunopathol. 74, 137–144.
Shaaltiel Y, Bartfeld D, Hashmueli S, et al (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol. J. 5, 579–590.
Jeoh T, Michener W, Himmel ME, et al (2008) Implications of cellobiohydrolase glycosylation for use in biomass conversion. Biotechnol. Biofuels 1, 10.
Acknowledgments
This work was supported by USDA SBIR Grant Phase I (2007-33610-17978) and Phase II (2008-33610-19482) to BioStrategies LC and a subaward to Arkansas Biosciences Institute (ABI) at Arkansas State University. Thanks to Nora Rubio, Jorge Ayala, and Nathan Stephens for technical support and help in standardization of direct ELISA, protein preparation for N-terminal sequencing, and endotoxin removal protocols, as part of BioStrategies LC projects. Thanks go as well to Drs. Brett Savary and Prasanna Vasu (ABI) for help in developing the MALDI-ToF procedures.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Medrano, G., Dolan, M.C., Condori, J., Radin, D.N., Cramer, C.L. (2012). Quality Assessment of Recombinant Proteins Produced in Plants. In: Lorence, A. (eds) Recombinant Gene Expression. Methods in Molecular Biology, vol 824. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-433-9_29
Download citation
DOI: https://doi.org/10.1007/978-1-61779-433-9_29
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-432-2
Online ISBN: 978-1-61779-433-9
eBook Packages: Springer Protocols